Mostrar o rexistro simple do ítem
Effect of long-term tafamidis treatment on health-related quality of life in patients with transthyretin amyloid cardiomyopathy
dc.contributor.author | Grogan, Martha | |
dc.contributor.author | Davis, Margot K. | |
dc.contributor.author | Crespo-Leiro, María Generosa | |
dc.contributor.author | Sultan, Marla B. | |
dc.contributor.author | Gundapaneni, Balarama | |
dc.contributor.author | Hanna, Mazen | |
dc.contributor.author | Stedile Angeli, Franca | |
dc.date.accessioned | 2024-06-10T09:25:47Z | |
dc.date.available | 2024-06-10T09:25:47Z | |
dc.date.issued | 2024-03-04 | |
dc.identifier.citation | Grogan M, Davis MK, Crespo-Leiro MG, Sultan MB, Gundapaneni B, Stedile Angeli F, Hanna M. Effect of long-term tafamidis treatment on health-related quality of life in patients with transthyretin amyloid cardiomyopathy. Eur J Heart Fail. 2024 Mar;26(3):612-615. | es_ES |
dc.identifier.issn | 1388-9842 | |
dc.identifier.uri | http://hdl.handle.net/2183/36848 | |
dc.description | Short report | es_ES |
dc.description.abstract | [Abstract] Aims: To evaluate the effect of long-term tafamidis treatment on health-related quality of life (HRQoL) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) enrolled in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension (LTE) study. Methods and results: We examined change from baseline in Kansas City Cardiomyopathy Questionnaire overall summary (KCCQ-OS) and clinical summary (KCCQ-CS) scores in patients who received tafamidis meglumine 80 mg for 30 months in ATTR-ACT and tafamidis (meglumine 80 mg or bioequivalent free acid 61 mg) for 30 months in the LTE study, and in patients who received placebo for 30 months in ATTR-ACT and tafamidis for 30 months in the LTE study. In ATTR-ACT, 176 and 177 patients were randomized to tafamidis 80 mg and placebo, respectively. Patients who continuously received tafamidis had a 6- to 7-point reduction in least squares (LS) mean (standard error) KCCQ-OS and KCCQ-CS scores at month 30 (-6.25 [1.53] and -7.48 [1.39]), with little or no further decline over the next 30 months (-5.92 [1.77] and -9.21 [1.88] at month 60). Patients who received placebo in ATTR-ACT had a 20-point reduction in LS mean KCCQ-OS and KCCQ-CS scores at month 30 (-19.60 [1.94] and -19.90 [2.01]), but the decline slowed after initiating tafamidis (-24.70 [3.04] and -25.30 [3.36] at month 60). Conclusion: Tafamidis reduced HRQoL decline in patients with ATTR-CM. Patients continuously treated with tafamidis for 60 months demonstrated stabilized HRQoL. In patients who initially received placebo in ATTR-ACT, tafamidis reduced the decline in HRQoL during the LTE study. | es_ES |
dc.language.iso | spa | es_ES |
dc.publisher | John Wiley & Sons | es_ES |
dc.relation.uri | https://doi.org/10.1002/ejhf.3190 | es_ES |
dc.rights | Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC-BY-NC-ND 4.0) | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Health‐related quality of life | es_ES |
dc.subject | Kansas City Cardiomyopathy Questionnaire | es_ES |
dc.subject | Tafamidis | es_ES |
dc.subject | Transthyretin amyloid cardiomyopathy | es_ES |
dc.title | Effect of long-term tafamidis treatment on health-related quality of life in patients with transthyretin amyloid cardiomyopathy | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.access | info:eu-repo/semantics/openAccess | es_ES |
UDC.journalTitle | European Journal of Heart Failure | es_ES |
UDC.volume | 26 | es_ES |
UDC.issue | 3 | es_ES |
UDC.startPage | 612 | es_ES |
UDC.endPage | 615 | es_ES |
dc.identifier.doi | 10.1002/ejhf.3190 |
Ficheiros no ítem
Este ítem aparece na(s) seguinte(s) colección(s)
-
INIBIC-ICATC - Artigos [178]